Clinical Trial Powered by Parsortix System Provides First-in-Class Data for Novel Approach to Cancer Treatment
A groundbreaking clinical trial powered by the Parsortix system has provided first-in-class data for a novel approach to cancer treatment. The trial, conducted by Professor Nicola Aceto’s team at ETH Zurich, Switzerland, used the Parsortix system to identify patients with highly metastatic circulating tumour cell (CTC) clusters for targeted treatment.
New Treatment Strategy Targets Metastasis Responsible for Majority of Cancer Deaths
The new treatment strategy has been hailed as an ‘uncharted opportunity’ to target metastasis, which is responsible for the vast majority of cancer deaths. By identifying patients with highly metastatic CTC clusters, researchers were able to administer a repurposed, FDA approved drug, digoxin, to treat metastatic breast cancer patients in a multi-centre Phase 1 clinical trial.
Impact on Individual Patients:
The use of the Parsortix system in cancer treatment could have a significant impact on individual patients, allowing for more targeted and personalized treatment options. By identifying patients with highly metastatic CTC clusters, doctors can tailor treatment plans to address the specific needs of each patient, potentially leading to improved outcomes and reduced side effects.
Impact on the World:
The groundbreaking research from Professor Nicola Aceto’s team at ETH Zurich has the potential to revolutionize cancer treatment on a global scale. By targeting metastasis, the leading cause of cancer-related deaths, the new treatment strategy could help save millions of lives worldwide. The use of the Parsortix system in clinical trials opens up a new frontier in cancer research and treatment, offering hope for patients and families affected by this devastating disease.
Conclusion
The publication of breakthrough research from ETH Zurich marks a significant milestone in the fight against cancer. The use of the Parsortix system in identifying patients with highly metastatic CTC clusters for targeted treatment represents a new paradigm in cancer care. As this research continues to evolve, we can expect to see even more innovative approaches to cancer treatment that have the potential to change the lives of patients around the world.
